Surface Ophthalmics, a Pleasanton CA-based pharmaceutical company, raised $25M in funding.
Investors included both new and existing investors made up of institutional, healthcare-focused, and other accredited investors, including members of the Surface Board of Directors.
The company intends to use the funds to advance its clinical programs in ocular diseases.
Led by Kamran Hosseini, MD, PhD, President and CEO, Surface Ophthalmics is a pharmaceutical company focused on the development and commercialization of innovative therapeutics for ocular diseases. Following the completion of current Phase II studies, the company will be positioned to begin enrolling patients in Phase III clinical trials, targeting FDA approval, for all three of its ophthalmic product candidates:
- one in chronic dry eye disease (SURF-100),
- one in acute dry eye (SURF-200), and
- one in pain and inflammation following ocular surgery (SURF-201).
These programs utilize Klarity® as the delivery vehicle, which is designed to enhance patient comfort as well as protect and rehabilitate the ocular surface. Developed by Richard L. Lindstrom, MD, inventor of Optisol GS (an advanced corneal preservation solution), Klarity is designed to enhance patient comfort as well as protect and rehabilitate the ocular surface pathology for patients with moderate-to-severe dry eye disease.